Cancer is accountable for the demise of numerous lives worldwide annually. In this research a derivative of lumichrome, 5,10-dihydro-7,8-dimethyl alloxazine was assessed for its anticancer property through docking study. It was appraised after performing molecular docking study of the 5,10-dihydro-7,8-dimethyl alloxazine, there was a strong interaction between multiple oncogenic target proteins like CDK2/CCNE2 (–8.5 kcal/mol), TDP2 (–8 kcal/mol), NAD-SIRT2 (–10.9 kcal/mol) and lung cancer and acute lymphoblastic leukemia (ALL). Additionally, according to ADMET analysis, the synthesized compound 5,10-dihydro-7,8-dimethyl alloxazine also has good physicochemical characteristics to be a drug candidate. Consequently, these verdicts will assist the development of a novel anti-lung cancer and anti-leukemic agent which will eventually improve the endurance of cancer patients.
BrayF., FerlayJ., SoerjomataramI., SiegelR.L., TorreL.A., JemalA., Global cancer statistics 2018 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians68 (2018), 394–424.
2.
HuangR., KimH.J., MinD.B., Photosensitizing Effect of Riboflavin, Lumiflavin, and Lumichrome on the Generation of Volatiles in Soy Milk, Journal of Agriculture and Food Chemistry54 (2006), 2359–2364.
3.
ChantarawongW., KuncharoenN., TanasupawatS., ChanvorachoteP., Lumichrome Inhibits Human Lung Cancer Cell Growth and Induces Apoptosis via a p53-Dependent Mechanism, Nutr Cancer71 (2019), 1390–1402.
4.
QaisN., EtuS.F., Antioxidant Activity of Lumichrome and Its Reduced Form, 5,10-Dihydro-7,8-dimethyl Alloxazine, IOSR Journal Pharm and Biological Science15 (2020), 50–53.
5.
DainaA., MichielinO., ZoeteV., SwissV., Target Prediction: updated data and new features for efficient prediction of protein targets of small molecules, Nucleic Acids Research47 (2019), 357–364.
6.
BermanH.M., BourneP.E., WestbrookJ., ZardeckiC., The protein data bank. In Protein Structure, CRC Press (2003), 394–410.
7.
DeLanoW.L. (2002) PyMOL
8.
HueyR., MorrisG.M., Using AutoDock 4 with AutoDocktools: a tutorial. The Scripps Research Institute, USA (2008), 54–56.
TrottO., OlsonA.J., Auto Dock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, Journal of Computational Chemistry31 (2010), 455–461.
11.
HodgsonJ., ADMET—turning chemicals into drugs, Natural Biotechnol19 (2001), 722–726.
12.
ChengF., LiW., ZhouY., ShenJ., WuZ., LiuG., Admet SAR: a comprehensive source and free tool for assessment of chemical ADMET properties, Journal of Chemical information and Modeling52 (2012), 3099–3105.
GaoP., WangH., YuJ., ZhangJ., YangZ., LiuM., miR-3607-3p suppresses nonsmall cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2, PLoS Genetics14 (2018), 1007790.
15.
BrambillaE., GazdarA., Pathogenesis of lung cancer signalling pathways: roadmap for therapies, European Respiratory Journal33 (2009), 1485–1497.
16.
ZhangY., XueQ., PanG., MengQ.H., TuoX., CaiX., Integrated Analysis of Genome Wide Copy Number Alterations and Gene Expression Profiling of Lung Cancer in Xuanwei, China, Plos One12 (2017), 0169098.
GrbesaI., PajaresM.J., Martínez-TerrobaE., Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients, Plos One10 (2015), 0124670.
19.
JinY., CaoQ., ChenC., DuX., JinB., PanJ., Tenovin-6-mediated inhibition of SIRT1/2 induces apoptosis in acute lymphoblastic leukemia (ALL) cells and eliminates ALL stem/progenitor cells, BMC Cancer15 (2015), 226.
20.
MorishimaT., KrahlA.C., NasriM., LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis, Blood134 (2019), 1159–1175.
21.
KozakoT., MelliniP., OhsugiT., Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines, BMC Cancer18 (2018), 791.
BianK., MuppaniN.R., ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells, Oncotarget7 (2016), 6665–6675.
24.
ChunxinL., LiuX., ZhengQ., Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer, Thorac Cancer9 (2018), 1166–1173.
25.
LiC., SunS.Y., KhuriF.R., LiR., Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond,(Georgetown,Tex.), Cell Cyc10 (2011), 3274–3283.
26.
LipinskiC.A., Lead-and drug-like compounds: the rule-of-five revolution, Drug Discov Today:Technol1 (2004), 337–341.
